Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02266355 · ClinicalTrials.gov registry record · Phase 1
Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02266355: Completed Phase 1 study, sponsored by Yale University.
NCT02266355 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02266355, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Pilot study to evaluate the activity of omalizumab in the prevention of recurrent oxaliplatin hypersensitivity reaction (HSR) in oxaliplatin-sensitive patients. The study will also evaluate the safety of omalizumab (Xolair) when administered in this setting.
Primary Outcome
Recurrent Oxaliplatin HSR in subjects treated with omalizumab
Interventions
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-02-27 |
| Phase | Phase 1 |
What the finished NCT02266355 record still lists
NCT02266355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Omalizumab is the first listed.
NCT02266355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02266355 about?
NCT02266355 is a clinical study titled "Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction". Pilot study to evaluate the activity of omalizumab in the prevention of recurrent oxaliplatin hypersensitivity reaction (HSR) in oxaliplatin-sensitive patients. The study will also evaluate the safety of omalizumab (Xolair) when administered in this setting.
What is the current status of trial NCT02266355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-11. Estimated completion is 2018-02-27.
What interventions are being tested in trial NCT02266355?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT02266355?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02266355's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia